Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (ACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04305769
Recruitment Status : Recruiting
First Posted : March 12, 2020
Last Update Posted : May 18, 2021
Sponsor:
Collaborator:
Imperial College London
Information provided by (Responsible Party):
Cirle Warren, MD, University of Virginia

Brief Summary:
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized persons aged 65 or older. Our hypothesis is that alanyl-glutamine supplementation will decrease recurrence and mortality from CDI and these outcomes will be associated with improvement of inflammatory markers and restoration of intestinal microbiota function.

Condition or disease Intervention/treatment Phase
Clostridioides Difficile Infection Clostridium Difficile Infection Clostridium Difficile Diarrhea Clostridia Difficile Colitis Drug: Alanyl-glutamine Phase 2

Detailed Description:

This is a Phase II randomized, placebo-controlled, double-blinded, dose-ranging study to determine optimal effective dose and safety of AQ between 0, 4, 24, and 44 g doses administered orally for ten days concurrent with standard treatment (oral vancomycin at UVa) among first time incident cases of uncomplicated CDI in hospitalized persons age 50 and older. Our hypothesis is that AQ will reduce recurrence (primary outcome) and mortality (secondary outcome) at 60 days post-treatment. Furthermore, the investigators hypothesize that alanyl-glutamine supplementation will be associated with decreased intestinal and systemic inflammation and improvement of intestinal microbial and metabolic profiles. The investigators plan to enroll 260 patients, equally divided into 4 arms. Upon enrollment, participants will be randomized to either receive AQ at 4, 24, or 44 g or placebo (water). Study agent is administered once a day, orally or enterally, if feeding tube is present. Because the investigators are enrolling subjects over a longer period of time, block randomization will be used to ensure that relative temporal balance is maintained throughout the trial. Participants will be followed up daily during treatment for adverse event monitoring and weekly for 60 days post-treatment for recurrences and survival. Blood, urine and stool specimens will be collected at days 0, 10 and 70 to assay for markers of inflammation and microbial and metabolic profiling.

The data set utilized for all initial baseline feature and demographic reporting will be the Intention to Treat Analysis Dataset, which will be comprised of all randomized participants. The primary dataset will be a Modified Intention to Treat Analysis Dataset for all endpoints, comprised of all participants who took at least one dose of study intervention (placebo or treatment), regardless of completeness of follow-up outcome data. The Safety Analysis Dataset will be all participants who took at least one dose of study intervention. The Per Protocol Analysis Dataset will be those patients who took at least 9 doses of study intervention for 9 days of the treatment period (10 days). Analysis will utilize ANOVA unless statistically significant differences in the distribution of baseline characteristics or features of non-normality are detected and relevant, at which point contingency utilization of ANCOVA, logistic regression, or other approaches as appropriate will be implemented. Treatment group level rates will be presented as incidence risk ratios relative to the control (placebo) group with 95% confidence intervals.

Safety endpoints will be evaluated on an individual AE by AE event via the DSMB and utilizing summary statistics during treatment and through duration of follow up. Adverse events will be presented by System Organ Class and will include information on start and stop date, severity, projected relationship, expectedness, and outcome and duration (the latter two after the event is considered to have concluded).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Block randomization will be applied to assign participants to one of the four study groups, either one of the three experimental (AQ) or control (placebo) group in 1:1:1:1 allocation from a list containing the randomized and blinded treatment assignments.
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled Trial
Actual Study Start Date : January 1, 2021
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Glutamine

Arm Intervention/treatment
Placebo Comparator: Alanyl-glutamine 0g Drug: Alanyl-glutamine
The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
Other Names:
  • Alagln
  • AQ
  • glutamine

Experimental: Alanyl-glutamine 4g Drug: Alanyl-glutamine
The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
Other Names:
  • Alagln
  • AQ
  • glutamine

Experimental: Alanyl-glutamine 24g Drug: Alanyl-glutamine
The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
Other Names:
  • Alagln
  • AQ
  • glutamine

Experimental: Alanyl-glutamine 44g Drug: Alanyl-glutamine
The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
Other Names:
  • Alagln
  • AQ
  • glutamine




Primary Outcome Measures :
  1. Number of participants with recurrent CDI. [ Time Frame: Within 60 days post-treatment ]
    Documented C difficile infection defined by presence of recurrent diarrhea with stool positive for C difficile assay necessitating treatment with anti-C. difficile antibiotic.


Secondary Outcome Measures :
  1. Number of participants who died post-study treatment [ Time Frame: Until 60 days post-treatment ]
    Documentation of death from any cause occurring during study treatment and 60 days after study treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 110 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged > 65 years
  4. Admitted in the hospital
  5. Presence of diarrhea*
  6. Stool positive for C. difficile tcdB and TcdB
  7. 1st episode of C. difficile infection, non-severe or severe uncomplicated
  8. Within 48 hours of receiving standard therapy (oral vancomycin at UVA)

Exclusion Criteria:

  1. At enrollment, presence of any of the following:

    • Hypotension or shock
    • Megacolon or moderate to severe ileus
    • Acute abdomen
    • Admission to intensive care unit
  2. Inability to tolerate oral or enteral medication
  3. Presence of other known infectious etiology of diarrhea
  4. Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) or other etiology of non-infectious diarrhea
  5. Enrollment in another investigational drug trial
  6. Current use of alternative treatment for CDI (e.g. antibiotics other than vancomycin or fidaxomicin; IVIg; fecal transplant).
  7. On probiotics and not willing to discontinue.
  8. Cirrhosis or in participants with ALT > 3X normal
  9. End stage renal disease, on dialysis, or creatinine clearance or estimated GFR of <30mL/min even after adequate hydration
  10. Life expectancy of < 6 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04305769


Locations
Layout table for location information
United States, Virginia
UVA Health Systems Recruiting
Charlottesville, Virginia, United States, 22903
Contact: Cirle Warren, M.D.    434-270-1082    CA6T@hscmail.mcc.virginia.edu   
Contact: MaryJane Strickland, B.S.,M.ed    4347601267    mjs7w@virginia.edu   
Principal Investigator: Cirle Warren, M.D.         
Sponsors and Collaborators
University of Virginia
Imperial College London
Layout table for additonal information
Responsible Party: Cirle Warren, MD, Associate Professor, University of Virginia
ClinicalTrials.gov Identifier: NCT04305769    
Other Study ID Numbers: 200046
First Posted: March 12, 2020    Key Record Dates
Last Update Posted: May 18, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All IPD that underlie results in publication
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: 6 months after publication
Access Criteria: To be determined later.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Clostridium Infections
Diarrhea
Signs and Symptoms, Digestive
Gram-Positive Bacterial Infections
Bacterial Infections